FDA official announcements and press releases

Studies Show Semaglutide Benefits for Type 2 Diabetes, Knee Pain Reduction by 50%

Nov 7, 2024, 11:00 AM

Recent studies have highlighted the significant health benefits of semaglutide, a GLP-1 receptor agonist, for adults with type 2 diabetes and other conditions. Semaglutide was found to significantly lower the risk of Alzheimer's disease compared to other antidiabetic medications. Additionally, it reduced kidney and cardiovascular disease events in type 2 diabetics and improved obesity-related heart failure with preserved ejection fraction in a placebo controlled trial. In a post hoc analysis, treatment with semaglutide, 2.4 mg, did not increase the risk of developing symptoms of depression or suicidal ideation compared to a placebo. A separate study indicated that weekly self-injections of semaglutide could reduce knee pain from moderate osteoarthritis by nearly 50%.